Skip to Content

WuXi Biologics (Cayman) Inc - Stock Quote 02269

Morningstar's WuXi Biologics (Cayman) Inc Stock Analysis

Valuation
Currency in

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

There is no Morningtar’s Analysis data available.

WuXi Biologics (Cayman) Inc's Company Profile

Business Description

WuXi Biologics (“WuXi”) is a contract development and manufacturing organization, or “CDMO,” for biologic drugs. It was founded in 2010 as part of WuXi AppTec and listed on the Hong Kong Stock Exchange in 2017. WuXi provides comprehensive services from conception to commercialization, including drug discovery, clinical and commercial manufacturing, and various support services such as process validation, viral clearance studies, product and cell line characterization, stability studies, and others. It does not conduct clinical trials.

Contact
No. 108, Meiliang Road, Mashan Binhu District
Wuxi, 214092, China, People's Republic of
T +86 51085353482
Sector Healthcare
Industry Biotechnology
Most Recent Earnings
Fiscal Year End Dec 31, 2022
Stock Type
Employees 9,864